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Background: The purpose of this study was to evaluate the efficacy of combined treatment
with the long-acting 5-hydroxytryptamine receptor-3 antagonist, palonosetron, the
neurokinin-1 receptor antagonist, oral aprepitant, and dexamethasone as primary anti-
emetic prophylaxis for cancer patients receiving highly emetogenic cisplatin-based
chemotherapy.
Methods: Chemotherapy-naı¨ve patients received the triple combination of palonosetron
(0.25 mg), aprepitant (125 mg on day 1 and 80 mg on days 2 and 3), and dexamethasone
(20 mg) from the beginning of highly emetogenic chemotherapy with cisplatin-based
(50 mg/m2) regimens. The primary endpoint was a complete response (no emetic epi-
sodes and no rescue antiemetics) during the days 1e6.
Results: Sixty-nine hospitalized patients receiving chemotherapy from September 2012 to
October 2014 were analyzed. Complete response of vomiting and nausea-free was achieved
in 97.1% and 85.5% of patients in the first cycle, respectively, and 96.7% and 83.6% of pa-
tients in the second cycle, respectively. Common adverse events in all 69 patients included
constipation (43%), hiccup (26%), and headache (4%).
Conclusion: The combination of palonosetron, aprepitant, and dexamethasone as primary
antiemetic prophylaxis for cancer patients with highly emetogenic cisplatin-based
chemotherapy is effective.ogy-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou,
Tel.: þ886 3 3281200 ext. 8825; fax: þ886 3 3278211.
l.com (C.-C. Liaw).
g Gung University.
ublishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND
/by-nc-nd/4.0/).
At a glance commentary
Scientific background of the subject
Chemotherapy-induced nausea and vomiting because
of cisplatin-based chemotherapy strongly affects the
quality of life of cancer patients. Primary antiemetic
prophylaxis with the first-generation 5-
hydroxytryptamine receptor-3 antagonist plus dexa-
methasone still resulted in about 20% patients experi-
encing acute and/or delayed emesis during the first cycle
of cisplatin-based chemotherapy.
What this study adds to the field
The triple combination of palonosetron, aprepitant, and
dexamethasone as primary antiemetic prophylaxis is
safe and highly effective in preventing chemotherapy-
induced nausea and vomiting in the days following
administration of highly emetogenic cisplatin-based
chemotherapy. Nearly, all the patients experienced no
episodes of vomiting and good control of nausea was
maintained following chemotherapy.
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nausea and vomiting (CINV) remains one of the most feared
side effects of chemotherapy. CINV as a consequence of
cisplatin-based chemotherapy strongly affects the quality of
life for cancer patients [1,2]. According to recent international
guidelines [3,4], cisplatin-based (at dose of 50 mg/m2) regi-
mens are considered to be highly emetogenic forms of
chemotherapy (HEC), with a >90% risk of inducing CINV [5].
The first-generation 5-hydroxytryptamine receptor-3
antagonist (5-HT3RAs), ondansetron, granisetron, dolasetron,
and tropisetron, have provided significant improvement in
the management of acute CINV [6] but have been shown to be
ineffective in controlling delayed CINV, even when adminis-
tered in multiple doses 24 h or more following chemotherapy
[7]. Palonosetron is a novel, potent, selective second-
generation 5-HT3RA with a longer half-life (40 h) [8], and a
higher receptor binding affinity (>30-fold) with respect to
other 5-HT3RAs [9]. The superiority of single-dose palonose-
tron (0.25 mg IV) over single-dose ondansetron (32 mg IV) or
dolasetron (100 mg IV) for the prevention of emesis and
delayed nausea has been demonstrated in phase III compar-
ative trials [10e13]. Aprepitant, the first approved substance P/
neurokinin-1 (NK1) receptor antagonist (NK1RA), has been
shown to significantly improve the prevention of acute and
delayed CINV following HEC [14]. A 3-day oral aprepitant
regimen in combination with standard antiemetics (ondan-
setron plus dexamethasone) was shown to offer enhanced
protection against emesis associated with anthracycline- and
cyclophosphamide-based breast cancer regimens or cisplatin-
based HEC when compared with standard antiemetics alone
[15,16]. All antiemetic guidelines are unanimous in recom-
mending a combination of aprepitant, dexamethasone, and a
5-HT3RA within the first 24 h for acute CINV with HEC [3,4,17].In a previous study [18], we investigated the efficacy of
adding aprepitant as a secondary antiemetic prophylaxis for
cases in which a first-generation 5-HT3RA plus dexametha-
sone failed to achieve full antiemetic protection during the
first cycle of a cisplatin-based regimen. Approximately 20% of
patients receiving primary antiemetic prophylaxis with gra-
nisetron plus dexamethasone experienced acute and/or
delayed emesis during the first cycle of cisplatin-based
chemotherapy. The addition of aprepitant as a secondary
antiemetic prophylaxis in subsequent cycles provided about
70% complete emesis protection in patients who failed pri-
mary prophylaxis. On the basis of these results, the aim of
this prospective study was to evaluate the efficacy of a com-
bination of the long-acting palonosetron, 3-day aprepitant
and dexamethasone as primary antiemetic prophylaxis in
patients receiving HEC (cisplatin 50 mg/m2), and to deter-
mine whether the antiemetic efficacy of the triple combina-
tion could be sustained.Materials and methods
Patients
Patients were enrolled in the study consecutively, and data
were collected prospectively. All chemo-naı¨ve patients in this
study were scheduled to receive chemotherapy with a dose of
at least 50 mg/m2 cisplatin followed immediately by a
continuous infusion of 5-fluorouracil (5-FU) with or without
other chemotherapeutic agents. Cisplatin was given on day 1
and the other drugs on day 1 and subsequent days. Partici-
pants were required to be at least 18 years of age, with no prior
history of cisplatin-containing chemotherapy, and the Eastern
Cooperative Oncology Group (ECOG) performance status
grades of 0e3. Individuals with a concurrent severe illness,
nausea, or vomiting in the period 24 h before chemotherapy,
other known causes of nausea, or vomiting (e.g., central ner-
vous system metastases, gastrointestinal obstruction, and
hypercalcemia), or concurrent therapy with corticosteroids or
benzodiazepines (unless given for night sedation) were
excluded from the study. Demographic data and patient
characteristics were examined and reported as frequencies
and percentages [Table 1]. All patients were hospitalized
during the administration of chemotherapy. The study was
approved by the Institutional Review Board of Chang Gung
Memorial Hospital (IRB No.: 103-3856B).
Antiemetic therapy
This was a single-institution study. The same chemothera-
peutic drug was used at identical doses during each treatment
cycle. Each chemotherapy cycle consisted of cisplatin
(50e100 mg/m2), and 20% mannitol (100e150 mL) adminis-
tered in 500 mL of normal saline for 3 h. Palonosetron (Aloxi,
Pierre Fabre, Medicament Production Aquitaine Pharm Inter-
national, Idron, France) 0.25 mg in 100 mL of normal saline
was given as a 30-min intravenous infusion before cisplatin
administration. Oral aprepitant (Emed, Merck Sharp, and
DohmeCorp., a subsidiary ofMerck and Co., Inc., PA, USA)was
administered once daily on day 1 at a dose of 125 mg, and at
Table 1 e Patient characteristics (n ¼ 69).
Variable Study population
Age, years
Median (range) 61 (32e81)
Gender, n (%)
Male 42 (61)
Female 27 (39)
Performance status, n (%)
0, 1 63 (91)
2 2 (3)
3 4 (6)
Primary site of malignancy, n (%)
Head and neck 2 (3)
Lung 1 (1)
Breast 2 (3)
Esophageal 18 (26)
Genitourinary 46 (67)
Chemotherapy regimen, dose (mg/m2), and days
F500D1-2/L30-35D1-2/G1000/P50 39 (57)
F500D1-2/L30-35D1-2/E100/P50 1 (1)
F500D1-2/L30-35D1-2/V30/P50 4 (6)
F500D1-2/L30-35D1-2/P50 7 (10)
FP 18 (26)
F1000D1-4/P100 1
F1000D1-4/P75 14
F1000D1-3/P75 1
F1000D1-3/P60 1
F660D1-4/P50 1
Abbreviations: F: 5-fluorouracil; L: Leucovorin; P: Cisplatin; E: Eto-
poside; G: Gemcitabine; V: Vinorelbine; D: Day.
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was administered before cisplatin or in solution with
cisplatin. In addition, all the patients received intravenous
dexamethasone (5 mg) every 12 h following cisplatin admin-
istration. Dexamethasone was discontinued after the
completion of chemotherapy. Intramuscular diphenhydra-
mine (30mg) or intravenousmetoclopramide (9mg)was given
to patients every 6 h as needed for an antiemetic rescue.
Response assessment and statistical analysis
Data on vomiting and nausea were recorded daily by the in-
vestigators (physicians and special nurses), commencing at
the time of patient admission. In addition, the patients were
asked to self-record their own symptoms daily during the days
after discharge. These records were collected in the out-
patient department or upon next admission. We recorded
whether or not each patient experienced CINV and theTable 2 e Incidence of CINV during the first chemotherapy.
Response Va Vd
n % n %
Complete response 69 100 67 97.1
Major response 0 0 0 0
Minor response 0 0 2 2.9
Failure to response 0 0 0 0
Abbreviations: Va: Acute vomiting; Vd: Delayed vomiting; Na: Acute nau
vomiting.severity of any episodes of CINV. A vomiting episode was
defined as involuntary, forceful expulsion of stomach con-
tents through the mouth. The efficacy of therapy on vomiting
was defined as follows: Complete response (no emetic episodes
and no rescue antiemetics); major response (1e2 emetic epi-
sodes); minor response (3e5 emetic episodes); and failure to
response (>5 emetic episodes) [19,20]. A nausea episode was
defined as a stomach distress with distaste for food and an
urge to vomit. The severity of nausea was rated by patients as
none, mild (no interference with daily life), moderate (some
interference with daily life), and severe (bedridden because of
nausea). The analysis of vomiting and nausea was performed
separately for day 1 (acute episodes) and days 2e6 (delayed
episodes). The severity of delayed vomiting was based on the
highest occurrence of emetic episodes between days 2 and 6,
and the intensity of delayed nauseawas recorded as the worst
nausea experienced over the same period.
The primary endpoint was complete response during the 6-
day study period. The secondary endpoints were the re-
sponses to treatment of acute and delayed emesis, and the
severity of acute and delayed nausea. Adverse events were
recorded. All data were analyzed using descriptive statistics.Results
Sixty-nine chemotherapy-naı¨ve patients were analyzed
consecutively from September 2012 to October 2014 at Linkou
Chang Gung Memorial Hospital. This study population con-
sisted of 42 men and 27 women, ranging in age from 32 to 81
years (median, 61 years). Most patients had stage IV disease
(81%) and ECOG performance status grades from 0 to 2 (94%).
More than half of our patients had primary malignancies of
the genitourinary system, including the bladder, ureter, renal
pelvis, and kidney. Detailed patient characteristics are listed
in Table 1. All the patients received chemotherapy containing
a cisplatin-based HEC regimen (cisplatin 50 mg/m2), and all
were undergoing concurrent treatment with other emeto-
genic drugs: 5-fluorouracil (100%), gemcitabine (57%), vinor-
elbine (6%), etoposide (1%). Totally, 38% of patients took
anti-depressants, anti-psychotics, hypnotics or sedatives for
insomnia, depressive disorder, or anxiety disorder.
All of the 69 patients who received palonosetron, aprepi-
tant, and dexamethasone for primary prophylaxis from
emesis were evaluated in the first cycle of chemotherapy. The
efficacy endpoints are summarized in Tables 2 and 3, Fig. 1.
The antiemetic efficacy data in the first cycle are listed inResponse Na Nd
n % n %
None 68 98.6 60 87.0
Mild 1 1.4 7 10.1
Moderate 0 0 2 2.9
Severe 0 0 0 0
sea; Nd: Delayed nausea; CINV: Chemotherapy-induced nausea and
Table 3 e Incidence of CINV during the second chemotherapy.
Response Va Vd Response Na Nd
n % n % n % n %
Complete response 61 100 59 96.7 None 59 96.7 52 85.2
Major response 0 0 2 3.3 Mild 2 3.3 8 13.1
Minor response 0 0 0 0 Moderate 0 0 1 1.7
Failure to response 0 0 0 0 Severe 0 0 0 0
Abbreviations: Va: Acute vomiting; Vd: Delayed vomiting; Na: Acute nausea; Nd: Delayed nausea; CINV: Chemotherapy-induced nausea and
vomiting.
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and nausea was achieved in 100% and 98.6% of patients,
respectively. Furthermore, complete protection from delayed
vomiting and nausea was obtained in 97.1% and 87.0% of pa-
tients, respectively. Delayed nausea ratings of none and mild
were obtained in 97.1% of patients. Overall, the complete
response of vomiting and nausea-free was achieved in 97.1%
and 85.5% of patients, respectively [Fig. 1A].
We planned for all the patients to receive two or more cy-
cles of chemotherapy, and the majority (88.4%) completed the
planned therapeutic scheme. Of the 69 patients who received
palonosetron, aprepitant, and dexamethasone for primary
emetic prophylaxis, 61 were evaluated in the second cycle ofFig. 1 e Illustration of the percentages of patients who
achieved complete response (no emesis and no rescue
therapy), and nausea-free (none of nausea) during the
overall study period (days 1e6), the acute phase (day 1), and
the delayed phase (days 2e6) in the first (A) and the second
(B) cycles of chemotherapy.chemotherapy. The other eight patients were not evaluated
for the following reasons: Not yet the time for the second cycle
of chemotherapy (n ¼ 4), progression or death due to
neoplasm (n ¼ 2), refusal of chemotherapy due to side effects
(n ¼ 1), or lost to follow-up (n ¼ 1). Two patients reduced
20e25% of the dose of cisplatin due to mild to moderate
delayed nausea in the first cycle of chemotherapy. The anti-
emetic efficacy data for the second treatment cycle are listed
in Table 3 and Fig. 1B. Complete protection from acute vom-
iting and nausea was attained in 100% and 96.7% of patients,
respectively. Complete protection from delayed vomiting and
nausea was achieved in 96.7% and 85.2% of patients, respec-
tively. Delayed nausea ratings of none ormildwere achieved in
98.3% of patients. Overall, the complete response of vomiting
and nausea-free was achieved in 96.7% and 83.6% of patients,
respectively [Fig. 1B].
Of the 61 patients who underwent cycles 1 and 2 of
chemotherapy, 45 patients (73.8%) experienced neither
nausea nor vomiting in either cycle. Four patients (6.5%) re-
fractory to antiemetic effects of agents still had delayed
nausea in both cycles. 12 patients (19.7%) experienced epi-
sodes of nausea or vomiting in one of the two cycles.
Most primary sites of malignancy in this study are geni-
tourinary and esophageal cancers [Table 1]. The standard
doses of cisplatin in genitourinary cancer and esophageal
cancer are 50 mg/m2 and 75 mg/m2, respectively. In the first
cycle of chemotherapy, 9% of genitourinary cancer patients,
and 28% of esophageal cancer patients experienced either
nausea or vomiting. In the second cycle of chemotherapy, 8%
of genitourinary cancer patients, and 39% of esophageal can-
cer patients experienced either nausea or vomiting.
The combination of palonosetron, aprepitant, and dexa-
methasone was generally well-tolerated, with most adverse
events mild in intensity. No major adverse events due to
antiemetic therapy were recorded. The most commonly re-
ported side effects in the first and the second cycles were
constipation (43% and 23%, respectively), hiccup (26% and
18%) and headache (4% and 3%), and there was a decreased
incidence of these adverse effects during the second cycle.Discussion
Cancer patients receiving HEC (e.g., cisplatin 50 mg/m2) are
at high risk of CINV (>90% frequency of emesis). As a result,
antiemetic guidelines recommend the use of a triple combi-
nation of 5-HT3RA, NK1RA, and dexamethasone [3,4]. The
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NK1RA, aprepitant [15,16,23], and the use of dexamethasone
[24] have been shown to further enhance the efficacy of anti-
emetic prophylaxis. Antiemetic prophylaxis should begin in
the first cycle of chemotherapy, and should be maintained
over subsequent cycles to afford continued protection [3,4]. In
this study, we evaluated the efficacy of a combination of
palonosetron, aprepitant, and dexamethasone as primary
antiemetic prophylaxis for patients receiving HEC (cisplatin
50 mg/m2). The proportion of patients with complete
response of vomiting was 100% during the acute interval (day
1), 97% during the delayed interval (days 2e6), and 97% during
the overall interval (days 1e6) in the first and second cycles.
Complete prevention of nausea and vomiting over both cycles
was achieved in 74% of patients. These results confirm that
the high efficacy obtained during the first chemotherapy cycle
was maintained over the subsequent cycle. Treatment was
well tolerated, with no unexpected adverse events. These data
showed that palonosetron in combination with aprepitant
and dexamethasone is safe and highly effective in preventing
CINV in the days following administration of HEC.
Delayed CINV (i.e., CINV occurring or persisting after 24 h
postchemotherapy) is particularly common in HEC [25e28].
According to Warr et al. [29], the triple combination of
ondansetron, aprepitant, and dexamethasone proved to be
superior over an entire 5-day study period (51% vs. 42%;
P¼ 0.015). However, therewas no significant difference during
the delayed period (49% vs. 55%; P¼ 0.064) [29]. We chose long-
acting palonosetron because of its superiority over ondanse-
tron in the prevention of emesis and delayed nausea [10e13].
In our study, most patients experienced no delayed vomiting
and more than 85% of patients reported being nausea-free
during the delayed phase.
Few trials have assessed the efficacy of the triple combi-
nation of palonosetron, aprepitant, and dexamethasone in
cancer patients receiving HEC [30e32]. One trial studying in
cancer patients receiving doxorubicin and cyclophosphamide-
based or cisplatin-based chemotherapy reported 93% of pa-
tients were emesis-free [30]. Longo et al. selected lung cancer
patients receiving chemotherapy with cisplatin 75 mg/m2
over multiple cycles of chemotherapy [31]. Their results
showed complete response rates of 74% and 82% during the
first and the last chemotherapy cycles, respectively. In a third
trial, gynecological cancer patients receiving chemotherapy
with cisplatin 50 mg/m2 were investigated [32]. The overall
complete response rate for the triple combination was 54.2%.
The reduced efficacy in this study may be related to the fact
that all the patients were female, and females are known to be
more susceptible than males to CINV. In this trial, we studied
the patients with different types of cancer, all of whom were
undergoing cisplatin-based HEC. Most patients had primary
malignancies of the genitourinary system and esophageal
cancer. One reason for the better results may be that higher
proportion of patients (77%) receiving cisplatin in doses of
50e60 mg/m2. The rest of patients receiving mainly 60e75 mg/
m2 of cisplatin may lead to higher rate of delayed nausea, but
would not increase the possibility of acute/delayed vomiting or
acute nausea after antiemetic protectionwith the combination
of palonosetron, aprepitant, and dexamethasone. In our study,
it's hard to make a conclusion of the efficacy of these threeanti-emetic agents for patients receiving more than 75 mg/m2
of cisplatin due to insufficient patient numbers with that dose.
Furthermore, the parts of patients taking anti-depressants,
anti-psychotics, hypnotics, or sedatives may influence the
results.
Prior to 2012, aprepitant was reimbursed by the National
Health Insurance (NHI) in Taiwan for patients who failed an
HEC regimen with 5-HT3RA and dexamethasone antiemetics.
Subsequently, the NHI policy was modified to included apre-
pitant reimbursement for patients in the first and the subse-
quent cycles of an HEC treatment regimen. One goal of our
studywas to evaluate the feasibility of this clinical scenario. In
a previous study [18], we investigated the efficacy of adding
aprepitant as a secondary prophylactic in cases failing to
achieve full antiemetic protection with 5-HT3RA and dexa-
methasone during the first cycle of a cisplatin-based regimen.
The results indicated that primary prophylactic use of grani-
setron plus dexamethasone provided complete protection
from cisplatin-induced emesis in 81% of patients. For those in
whom primary prophylaxis failed, secondary antiemetic pro-
phylaxis with aprepitant provided complete protection from
vomiting in 65% and 77% of patients in the second and third
cycles of treatment, respectively. In the present study, apre-
pitant was included in as a primary prophylactic in a triple
antiemetic combination, and nearly all the patients achieved
complete protection from vomiting, from the first cycle of
chemotherapy. Control of CINV could increase patient
adherence to cancer treatment regimens and provide an
acceptable quality of life. We suggested that aprepitant-
containing primary antiemetic prophylaxis is a feasible and
effective means of preventing CINV in patients treated with
cisplatin-based HEC.
A limitation of the present study was the relatively small
sample size to provide precise and powerful results.
Furthermore, the study was not randomized and did not
include a control arm. Additional research is needed to further
clarify the role of aprepitant in this setting and to determine
whether the incremental benefit of triplet therapy with pal-
onosetron and dexamethasone plus aprepitant when
compared with palonosetron and dexamethasone alone is
worth the additional cost in patients receiving HEC.
Over the last decade, the effectiveness of antiemetic
treatment has improved gradually at Chang Gung Memorial
Hospital in Taiwan [18,33]. More than 90% of our patients
achieved complete protection from acute nausea and vomit-
ing. The proportion of HEC patients achieving complete pro-
tection from delayed nausea and vomiting has improved from
approximately 60% and 70% of the patients to 85% and 95%,
respectively. The present study investigated the usefulness of
palonosetron, in combination with aprepitant and dexa-
methasone, to prevent both acute and delayed CINV following
cisplatin-based HEC. More than 95% of patients experienced
no episodes of vomiting and maintained good control of
nausea over the 6 days following chemotherapy.Source of support
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